

Douglas B Evans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/339008/publications.pdf>

Version: 2024-02-01

147
papers

6,652
citations

126858

33
h-index

66879

78
g-index

149
all docs

149
docs citations

149
times ranked

7225
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 567-610.	2.4	1,738
2	Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head. <i>Journal of Clinical Oncology</i> , 2008, 26, 3496-3502.	0.8	684
3	Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration. <i>Annals of Surgical Oncology</i> , 2001, 8, 123-132.	0.7	326
4	Adrenal cortical carcinoma. <i>World Journal of Surgery</i> , 2001, 25, 914-926.	0.8	295
5	Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. <i>BMC Cancer</i> , 2018, 18, 335.	1.1	271
6	Diagnostic Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Patients With Presumed Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2003, 7, 118-128.	0.9	248
7	Surgical Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement. <i>Annals of Surgical Oncology</i> , 2009, 16, 1736-1744.	0.7	200
8	Cost and Utilization Impact of a Clinical Pathway for Patients Undergoing Pancreaticoduodenectomy. <i>Annals of Surgical Oncology</i> , 2000, 7, 484-489.	0.7	178
9	Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 271, 740-747.	2.1	127
10	Parathyroid Carcinoma: An Update on Treatment Outcomes and Prognostic Factors from the National Cancer Data Base (NCDB). <i>Annals of Surgical Oncology</i> , 2015, 22, 3990-3995.	0.7	116
11	Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. <i>Surgery</i> , 2016, 159, 893-900.	1.0	114
12	Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 681-688.	0.7	111
13	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. <i>JAMA Surgery</i> , 2016, 151, 365.	2.2	102
14	Arterial resection at the time of pancreatectomy for cancer. <i>Surgery</i> , 2014, 155, 919-926.	1.0	94
15	Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration. <i>Annals of Surgical Oncology</i> , 2001, 8, 123-132.	0.7	94
16	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2016, 23, 134-141.	0.7	76
17	CXCL12 Chemokine Expression Suppresses Human Pancreatic Cancer Growth and Metastasis. <i>PLoS ONE</i> , 2014, 9, e90400.	1.1	74
18	Prophylactic Central Compartment Neck Dissection in Papillary Thyroid Cancer and Effect on Locoregional Recurrence. <i>Annals of Surgical Oncology</i> , 2018, 25, 2526-2534.	0.7	73

#	ARTICLE	IF	CITATIONS
19	A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2018, 268, 610-619.	2.1	58
20	Phase I Study of Concomitant Gemcitabine and IMRT for Patients with Unresectable Adenocarcinoma of the Pancreatic Head. <i>International Journal of Gastrointestinal Cancer</i> , 2001, 30, 123-132.	0.4	57
21	Pancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling. <i>Cancer Research</i> , 2015, 75, 3529-3542.	0.4	56
22	Chemokines and chemokine receptors: Update on utility and challenges for the clinician. <i>Surgery</i> , 2014, 155, 961-973.	1.0	55
23	Locally advanced pancreas cancer: Staging and goals of therapy. <i>Surgery</i> , 2018, 163, 1053-1062.	1.0	53
24	A Single Parathyroid Hormone Level Obtained 4 Hours after Total Thyroidectomy Predicts the Need for Postoperative Calcium Supplementation. <i>Journal of the American College of Surgeons</i> , 2014, 219, 757-764.	0.2	48
25	Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 41-46.	0.3	44
26	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. <i>Annals of Surgical Oncology</i> , 2016, 23, 126-133.	0.7	42
27	Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. <i>American Journal of Surgery</i> , 2021, 222, 10-17.	0.9	41
28	Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. <i>Surgery</i> , 2019, 166, 277-285.	1.0	40
29	Thyroid Cancer: 1999 Update and Evaluation of Solitary Thyroid Nodules. <i>Annals of Surgical Oncology</i> , 2000, 7, 376-398.	0.7	39
30	Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer. <i>Surgical Clinics of North America</i> , 2016, 96, 1351-1370.	0.5	39
31	Thyroid cancer in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27025.	0.8	39
32	Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 1998, 5, 242-250.	2.0	37
33	Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. <i>Journal of Surgical Oncology</i> , 2015, 112, 164-172.	0.8	36
34	How I do it: Alternative method for exposure of the retropancreatic mesenteric vasculature during total pancreatectomy. , 1996, 61, 163-165.		32
35	Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells. <i>International Journal of Gastrointestinal Cancer</i> , 1996, 19, 31-38.	0.4	31
36	Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)? <i>Journal of Clinical Oncology</i> , 2016, 34, 443-443.	0.8	31

#	ARTICLE	IF	CITATIONS
37	Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. <i>Laboratory Investigation</i> , 2017, 97, 302-317.	1.7	30
38	Total Neoadjuvant Therapy for Operable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2246-2256.	0.7	29
39	Cosyntropin stimulation testing on postoperative day 1 allows for selective glucocorticoid replacement therapy after adrenalectomy for hypercortisolism: Results of a novel, multidisciplinary institutional protocol. <i>Surgery</i> , 2016, 159, 259-266.	1.0	28
40	Tumor Suppressor Gene Smad4/DPC4, Its Downstream Target Genes, and Regulation of Cell Cycle. <i>Annals of the New York Academy of Sciences</i> , 1999, 880, 31-37.	1.8	27
41	Persistent/Recurrent Primary Hyperparathyroidism: Does the Number of Abnormal Glands Play a Role?. <i>Journal of Surgical Research</i> , 2020, 246, 335-341.	0.8	26
42	EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 6135-6144.	3.2	26
43	Resectable pancreatic cancer: The role for neoadjuvant/preoperative therapy. <i>Hpb</i> , 2006, 8, 365-368.	0.1	25
44	Evolution of the Management of Resectable Pancreatic Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 772-778.	2.5	24
45	Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?. <i>Journal of Surgical Oncology</i> , 2016, 114, 581-586.	0.8	23
46	Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique. <i>Annals of Surgical Oncology</i> , 1996, 3, 241-246.	0.7	21
47	Neoadjuvant Therapy for Localized Pancreatic Cancer. <i>Annals of Surgery</i> , 2015, 261, 18-20.	2.1	21
48	Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 460.	1.3	20
49	Invited commentary: Medullary thyroid cancer: The importance of RET testing. <i>Surgery</i> , 2007, 141, 96-99.	1.0	19
50	Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. <i>Journal of Oncology Practice</i> , 2016, 12, 915-923.	2.5	19
51	Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls. <i>Thyroid</i> , 2018, 28, 1462-1467.	2.4	19
52	Perioperative Gemcitabine+ Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 4489-4497.	0.7	19
53	Management of suspected adrenal metastases at 2 academic medical centers. <i>American Journal of Surgery</i> , 2016, 211, 664-670.	0.9	18
54	A Multi-Institutional Comparison of Adrenal Venous Sampling in Patients with Primary Aldosteronism: Caution Advised if Successful Bilateral Adrenal Vein Sampling is Not Achieved. <i>World Journal of Surgery</i> , 2018, 42, 466-472.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 548-558.	0.6	18
56	Cell cycle regulation of human pancreatic cancer by tamoxifen. <i>Annals of Surgical Oncology</i> , 1998, 5, 342-349.	0.7	17
57	What Makes a Pancreatic Cancer Resectable?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 300-305.	1.8	17
58	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3773-3777.	0.8	17
59	Papillary carcinoma of the thyroid: Balancing principles of oncology with emerging technology. <i>Surgery</i> , 2011, 150, 1015-1022.	1.0	16
60	Focused parathyroidectomy with intraoperative parathyroid hormone monitoring in patients with lithium-associated primary hyperparathyroidism. <i>Surgery</i> , 2013, 153, 718-722.	1.0	16
61	Institutional experience with lateral neck dissections for thyroid cancer. <i>Surgery</i> , 2015, 158, 972-980.	1.0	16
62	Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2016, 114, 291-295.	0.8	16
63	Preoperative Chemoradiation for Pancreatic Cancer. <i>Seminars in Oncology</i> , 2005, 32, 25-29.	0.8	15
64	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Long-term Survival. <i>World Journal of Surgery</i> , 2016, 40, 706-714.	0.8	15
65	Parathyroidectomy for primary hyperparathyroidism improves sleep quality: A prospective study. <i>Surgery</i> , 2017, 161, 25-34.	1.0	15
66	Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. <i>Clinical Cancer Research</i> , 2021, 27, 226-236.	3.2	15
67	Distal splenorenal and mesocaval shunting at the time of pancreatectomy. <i>Surgery</i> , 2019, 165, 298-306.	1.0	14
68	Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 275, e229-e237.	2.1	14
69	Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis. <i>Modern Pathology</i> , 2022, 35, 96-105.	2.9	13
70	The Effect of Thyroiditis on the Yield of Central Compartment Lymph Nodes in Patients with Papillary Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 4181-4186.	0.7	12
71	Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. <i>Abdominal Radiology</i> , 2018, 43, 351-363.	1.0	11
72	A postoperative parathyroid hormone-based algorithm to reduce symptomatic hypocalcemia following completion/total thyroidectomy: A retrospective analysis of 591 patients. <i>Surgery</i> , 2018, 164, 746-753.	1.0	11

#	ARTICLE	IF	CITATIONS
73	Volume-Outcome in Cancer Surgery: Why has the Data Not Affected Policy Change?. Annals of Surgical Oncology, 2014, 21, 4056-4058.	0.7	10
74	Association between body mass index and multigland primary hyperparathyroidism. Journal of Surgical Research, 2016, 202, 132-138.	0.8	10
75	Disparities in access to care and outcomes in patients with adrenocortical carcinoma. Journal of Surgical Research, 2017, 213, 138-146.	0.8	10
76	Confirmation of Parathyroid Tissue: Are Surgeons Aware of New and Novel Techniques?. Journal of Surgical Research, 2020, 246, 139-144.	0.8	10
77	Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. Hpb, 2020, 22, 1675-1685.	0.1	10
78	An Institutional experience with primary hyperparathyroidism in the elderly over two decades. American Journal of Surgery, 2021, 222, 549-553.	0.9	10
79	Selective Glucocorticoid Replacement Following Unilateral Adrenalectomy for Hypercortisolism and Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e538-e547.	1.8	10
80	Replaced gastroduodenal artery: Added benefit of the "artery first" approach during pancreaticoduodenectomy—a case report. International Journal of Surgery Case Reports, 2016, 23, 93-97.	0.2	9
81	Analysis of an institutional protocol for thyroid lobectomy: Utility of routine intraoperative frozen section and expedited (overnight) pathology. Surgery, 2016, 159, 512-517.	1.0	9
82	Using parathyroid hormone spikes during parathyroidectomy to guide intraoperative decision-making. Journal of Surgical Research, 2017, 209, 162-167.	0.8	9
83	5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, e14613-e14613.	0.8	9
84	Enrichment Methods for Mutation Detection. Annals of the New York Academy of Sciences, 2000, 906, 31-38.	1.8	8
85	Delayed Calcium Normalization After Presumed Curative Parathyroidectomy is Not Associated with the Development of Persistent or Recurrent Primary Hyperparathyroidism. Annals of Surgical Oncology, 2016, 23, 2310-2314.	0.7	8
86	Health Care Disparities and the Future of Pancreatic Cancer Care. Surgical Oncology Clinics of North America, 2021, 30, 759-771.	0.6	8
87	Neoadjuvant therapy for pancreatic cancer in patients older than age 75.. Journal of Clinical Oncology, 2014, 32, 287-287.	0.8	8
88	Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. Endocrine, 2018, 61, 216-223.	1.1	7
89	Utility of Epinephrine Levels in Determining Adrenal Vein Cannulation During Adrenal Venous Sampling for Primary Aldosteronism. Endocrine Practice, 2022, 28, 276-281.	1.1	7
90	Preoperative chemoradiation for adenocarcinoma of the pancreas: M.D. Anderson experience. Journal of Surgical Oncology, 1995, 11, 132-140.	1.4	6

#	ARTICLE	IF	CITATIONS
91	Commentary on: Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study. <i>Surgery</i> , 2017, 161, 472-474.	1.0	6
92	Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 235-242.	0.9	6
93	Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151485.	0.6	6
94	Screening guidelines and recommendations for patients at high risk of developing endocrine cancers. <i>Journal of Surgical Oncology</i> , 2020, 121, 975-983.	0.8	6
95	Chemoradiation for Localized Pancreatic Cancer: Another Perspective. <i>Annals of Surgical Oncology</i> , 1999, 6, 4-7.	0.7	5
96	Perioperative Management and Outcomes of Hyperthyroid Patients Unable to Tolerate Antithyroid Drugs. <i>World Journal of Surgery</i> , 2020, 44, 3770-3777.	0.8	5
97	Actionable targets in pancreatic cancer detected by immunohistochemistry (IHC), microarray (MA) fluorescent in situ hybridization (FISH), and mutational analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4013-4013.	0.8	5
98	Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG).. <i>Journal of Clinical Oncology</i> , 2016, 34, 397-397.	0.8	5
99	Underdiagnosis of primary hyperparathyroidism in patients with osteoarthritis undergoing arthroplasty. <i>Surgery</i> , 2021, , .	1.0	5
100	Low 24-hour urine calcium levels in patients with sporadic primary hyperparathyroidism: is further evaluation warranted prior to parathyroidectomy?. <i>American Journal of Surgery</i> , 2015, 210, 123-128.	0.9	4
101	Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level. <i>Frontiers in Oncology</i> , 2021, 11, 606820.	1.3	4
102	Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer—Medical college of Wisconsin perspective. <i>Journal of Surgical Oncology</i> , 2021, 123, 1405-1413.	0.8	4
103	Pancreaticoduodenectomy and Vascular Reconstruction. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 731-746.	0.6	4
104	Updated survival analysis of preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4051-4051.	0.8	4
105	Central compartment lymph node dissection for differentiated thyroid cancer: review of the literature. <i>International Journal of Endocrine Oncology</i> , 2014, 1, 41-48.	0.4	3
106	Intraoperative ex vivo parathyroid aspiration: A point-of-care test to confirm parathyroid tissue. <i>Surgery</i> , 2016, 160, 850-857.	1.0	3
107	A Novel Reconstruction Technique During Pancreaticoduodenectomy After Roux-En-Y Gastric Bypass: How I do it. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1186-1191.	0.9	3
108	Locally advanced pancreatic cancer: staging, operability, and the importance of multimodality therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 497-500.	0.7	3

#	ARTICLE	IF	CITATIONS
109	Commentary: Surgery for locally advanced pancreatic cancer after neoadjuvant therapy. <i>Surgery</i> , 2021, 169, 1032-1033.	1.0	3
110	Updates on the Management of Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, xvii-xviii.	0.6	3
111	The Clinical Utility of Preoperative Thyroglobulin for Surgical Decision Making in Thyroid Disease. <i>Journal of Surgical Research</i> , 2022, 270, 230-235.	0.8	3
112	Editorial: Small, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors: Observation becoming standard of care?. <i>Surgery</i> , 2019, 166, 164-165.	1.0	2
113	Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. <i>Surgery</i> , 2021, 169, 629-635.	1.0	2
114	Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. <i>Hpb</i> , 2020, 22, 1745-1752.	0.1	2
115	Association of decline in serum Ca19-9 after neoadjuvant therapy with improved survival among borderline resectable pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15082-e15082.	0.8	2
116	Can the sequence of chemotherapy regimens influence outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?. <i>Journal of Clinical Oncology</i> , 2016, 34, 428-428.	0.8	2
117	Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 879-889.	2.7	2
118	Lessons learned from investigator-initiated clinical trials for localized pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2022, 125, 69-74.	0.8	2
119	Wide Variability in Catecholamine Levels From Adrenal Venous Sampling in Primary Aldosteronism. <i>Journal of Surgical Research</i> , 2022, 277, 1-6.	0.8	2
120	MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in <i>KRAS</i> -mutated advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16260-e16260.	0.8	2
121	Treatment sequencing for pancreatic neuroendocrine tumors: daring to challenge the status quo. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 545-547.	0.6	1
122	Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4136-4136.	0.8	1
123	Confirmation of Feasibility of Selective Glucocorticoid Replacement Following Unilateral Adrenalectomy for Hypercortisolism and Primary Aldosteronism. <i>Journal of the Endocrine Society</i> , 2021, 5, A80-A81.	0.1	1
124	Tips for authors of surgical manuscripts from senior reviewers. <i>Surgery</i> , 2021, 170, 341-344.	1.0	1
125	Phase II clinical trial of biomarker-directed therapy for localized pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4147-TPS4147.	0.8	1
126	Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 589-589.	0.8	1

#	ARTICLE	IF	CITATIONS
127	Variation in parathyroid adenoma size in patients with sporadic, primary hyperparathyroidism: small gland size does not preclude single gland disease. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2067-2073.	0.8	1
128	Thyroid and adrenal cancer. , 2003, , 294-299.		0
129	Response to comments on: Cosyntropin stimulation testing on postoperative day 1 allows for selective glucocorticoid replacement therapy following adrenalectomy for hypercortisolism: Results of a novel, multidisciplinary institutional protocol. <i>Surgery</i> , 2016, 160, 249-250.	1.0	0
130	Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer?. <i>Practical Radiation Oncology</i> , 2017, 7, e449-e455.	1.1	0
131	Impact of KRAS alterations in localized pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 431-431.	0.8	0
132	Precision Medicine for Pancreatic Cancer. <i>Advances in Oncology</i> , 2021, 1, 63-71.	0.1	0
133	Clinical outcomes in pancreatic ductal adenocarcinoma (PDAC) patients with underlying autoimmune disease (AID).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16233-e16233.	0.8	0
134	Local control in resectable and borderline resectable pancreatic cancer (PCa) treated with preoperative chemoradiation using IMRT or chemotherapy alone.. <i>Journal of Clinical Oncology</i> , 2013, 31, 282-282.	0.8	0
135	Rapid immunohistochemical analysis of pancreatic cytology from endoscopic ultrasound-guided fine-needle aspirates: A prospective clinical trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 400-400.	0.8	0
136	Should functional renal scans be obtained prior to upper abdominal radiation for pancreatic cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 442-442.	0.8	0
137	Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 282-282.	0.8	0
138	Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15766-e15766.	0.8	0
139	Targeting of the Histone 3 Lysine 9 Methyltransferase Pathway in Kras-Induced Cell Growth and Pancreatic Cancer. <i>FASEB Journal</i> , 2018, 32, 826.11.	0.2	0
140	A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4112-4112.	0.8	0
141	A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated chemoradiation for resectable, borderline-resectable, or locally advanced type a pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4167-TPS4167.	0.8	0
142	Utilization of somatic comprehensive genomic profiling (CGP) to identify patients (pts) with pancreatic cancer (PC) that harbor germline DNA damage repair (DDR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 760-760.	0.8	0
143	Impact of CDKN2A/b status in pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 759-759.	0.8	0
144	Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
145	Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response.. Journal of Clinical Oncology, 2022, 40, 596-596.	0.8	0
146	Neoadjuvant Treatment of Pancreatic Cancer: Borderline-Resectable Disease. , 0, , 727-740.		0
147	Neoadjuvant radiation case volume and associated with margin-negative resection rates in patients with pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, e16281-e16281.	0.8	0